Sun Pharmaceutical, Zydus Lifesciences and Oriental Rail Infrastructure to see some action today

19 Mar 2025 Evaluate

Sun Pharmaceutical Industries’ subsidiary -- TARO Pharmaceuticals Inc. has completed 100% acquisition of Antibe Therapeutics Inc., Canada for a total consideration of CAD 4.5 million.  Earlier, TARO Pharmaceuticals Inc. had entered into an agreement with Antibe Therapeutics Inc., Canada, pursuant to which Sun Pharma had agreed to acquire 100% stake in Antibe Therapeutics Inc.

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Apalutamide Tablets, 60 mg (Erleada Tablets, 60 mg). Apalutamide is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-sensitive prostate cancer. Apalutamide tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad. 

Oriental Rail Infrastructure has secured order worth Rs 1.89 crore from Integral Coach Factory (ICF), Chennai, Indian Railways for Supply and Installation of 18 sets of One Coach Set of Seats (with fixing arrgt) for Second AC Chair Car coaches. 

GR Infraprojects has received Letter of Acceptance (LoA) from National Highways Authority of India (NHAI) (Ministry of Road, Transport & Highways) for Construction of Agra - Gwalior Greenfield Road. The NHAI Estimated Project Cost is Rs 4262.78 crore and the project is to be completed within 910 days from Appointed date.

Magnum Ventures has raised Rs 15 crore through the allotment of 1,500 Listed, Rated, Secured, Redeemable, Non-Convertible Debentures (NCD) (Tranche-II), of the face value of Rs 1,00,000 on a private placement basis. The Debt Raise Committee of the Company has at its meeting held on March 18, 2025, allotted the same.  

Premier Explosives has received an export order for Rs 18.90 crore for supply of Defence Explosives to be delivered within a period of 5 months. 

NTPC has planned to issue unsecured non-convertible debentures (NCDs) of Rs 4,000 crore on March 20, 2025, through private placement at a coupon of 7.26% p.a. for a tenor of 15 years, maturing on March 20, 2040, under the board resolution dated June 29, 2024 and subsequent approval obtained through shareholders’ resolution dated August 29, 2024. This is the first issue of debentures under the above mentioned approval. Proceeds will be utilized for, inter alia, funding of capital expenditure, refinancing of existing loans and other general corporate purposes. The debentures are proposed to be listed on NSE. 

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×